

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Duration between VRA and First Patient (days)	Benchmark Met	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
13/LO/1082	Revascularisation or medical therapy in elderly patients with acute anginal syndromes.	09/12/2014	11/09/2015	276	No						Y					Participants must be over the age of 80 years for this study and are mostly either too unwell to be eligible or so well that randomisation would be inappropriate.	Neither
08/H1102/112	Safety and efficacy of intensive versus guideline antiplatelet therapy in high risk patients with recent ischaemic stroke or transient ischaemic attack: a randomised controlled trial	03/02/2015	10/07/2015	157	No					Y						Study not activated at site by sponsor due to NHS Provider staff jury service and annual leave. Site now activated and first patient recruited on 10/07/2015.	NHS Provider
12/EM/0369	Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage TICH2	27/02/2015	22/04/2015	54	Yes					Y						Study not activated at site by sponsor due to NHS Provider staff jury service and annual leave. Study now active and first patient recruited.	NHS Provider
15/WA/0189	Bedside Inotropy - validation of a non-invasive technique to rapidly measure cardiac contractility	18/05/2015	08/06/2015	21	Yes												
10/H0802/46	Revascularisation for Ischaemic Ventricular Dysfunction (REVIVED)	12/06/2015			No						Y					This study has a difficult patient population with unfortunately 40-50% of patients dying before they can be approached.	Neither
13/SC/0645	Pre-eclampsia in Hospital: Early Induction or Expectant Management	18/03/2015	01/07/2015	105	No					Y						Staff sickness and annual leave. First patient recruited 01/07/2015.	NHS Provider
14/SC/1223	A phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.	22/06/2015			No				Y	Y	Y					Delay in Site Initiation Visit by sponsor and issues with NHS Provider Pharmacy. Site activated by sponsor on 21/10/2015. Medical staff availability and lack of patients seen have impacted on recruitment in Q3.	Both

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Duration between VRA and First Patient (days)	Benchmark Met	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
14/SC/0033	PHASE 3 MULTI CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF 04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	07/07/2015	10/12/2015	156	No				Y	Y						Site not activated by sponsor until 01/10/2015. PI then on annual leave.	Both
14/SC/0032	PHASE 3 MULTI CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF 04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	07/07/2015	10/12/2015	156	No				Y	Y						Site not activated by sponsor until 01/10/2015. PI then on annual leave.	Both
14/YH/0085	FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab	09/07/2015	19/08/2015	41	Yes												
11/SS/0100	A multicentre randomised trial to establish the effect(s) of routine administration of Fluoxetine for six months in patients with a recent stroke	29/07/2015	14/09/2015	47	Yes												
15/SC/0085	A feasibility study with a crossover design to assess the diagnostic accuracy of acetic acid targeted biopsies versus non targeted biopsies (current practice) for detection of dysplasia during Barrett's surveillance: the ABBA study.	17/09/2015	07/12/2015	81	No					Y						Very recently approved study. Staff availability issues over the summer holiday period.	NHS Provider
15/LO/0802	The effect of standard versus high energy, low volume oral nutritional supplements in children requiring nutritional support ? a pilot trial	28/07/2015	12/10/2015	76	No					Y						Staff availability issues over the summer holiday period.	NHS Provider

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Duration between VRA and First Patient (days)	Benchmark Met	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
15/WS/0061	A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure	09/09/2015			No							Y				Suitable patients are being screened, however of the few eligible patients seen, the majority of patients have declined to participate.	Neither
13/NS/0155	A multicentre randomised controlled trial comparing laparoscopic supracervical hysterectomy with second generation endometrial ablation for the treatment of heavy menstrual bleeding (HEALTH)	04/11/2015			Within 70 Days						Y					No eligible patients seen to date.	Neither
14/EM/0172	Outcome After Selective Early Treatment for Closure of Patent Ductus Arteriosus in Preterm Babies	13/10/2015			No										Y	We are a continuing care site for this study and therefore will not be recruiting any participants.	Neither
15/LO/1035	Multinational Abluminal Sirolimus Coated BiOEngineered StenT The MASCOT Post Marketing Registry	18/09/2015	30/10/2015	42	Yes												
15/SC/0448	A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care.	12/10/2015	09/12/2015	58	Yes												

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Duration between VRA and First Patient (days)	Benchmark Met	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
15/SW/0194	A randomized, double-blind, placebo-controlled, parallel-group, multicenter, eventdriven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease	12/10/2015	06/01/2016	86	No							Y				No response from potential participants from invitation letters.	Neither